Leadership Team

Our talented scientific staff has more than two centuries of combined experience in protein and small molecule bioanalysis, structure identification, genetic toxicology, safety assessment, and risk management in both discovery and development within the pharmaceutical industry.  We have assembled a team that has worked together for the last five years and has contributed to one of the healthiest drug pipelines in the industry and to the registration of novel blockbuster drugs.

Michael Schlosser serves as the President of MBR. As president, his responsibilities include providing strategic direction, forming alliances with complementary CROs and experts, and ensuring the highest standards of scientific integrity.

Mike has 19 years of experience within the pharmaceutical industry and 25 years of experience in toxicology. Prior to founding MBR, he was Senior Director of Safety Sciences at Pfizer/Pharmacia (formerly Searle/Monsanto). Prior to that, he served as the Director of Experimental Toxicology and Pathology at Astra Pharmaceuticals. Mike was also the Head of Experimental Toxicology at Ciba-Geigy Pharmaceuticals.

Mike holds a Ph.D. in toxicology and pharmacology from the University of Mississippi. He was certified as Diplomate of the American Board of Toxicology (DABT) in 1990.

Marie Rock is the Vice President of MBR’s Protein Bioanalysis group. Her responsibilities include directing and designing method development and validation experiments, interpreting and reporting results, and preparing summary regulatory documents.

Marie has more than 25 years of experience in the pharmaceutical industry.  At Pfizer/Pharmacia, she was Director of Analytical Methodologies for Experimental Medicine.  At Searle/Monsanto, she was Senior Research Advisor for the Clinical Pathology/Immunoassay Laboratory in Metabolism and Safety Evaluation.  Marie was also the Head of Drug Metabolism at Nova Pharmaceuticals.   Prior to that, she was Director of Immunoassays at Ortho (J&J) Pharmaceuticals.  Marie also served as the Vice President of R&D for Diagnon and Director of Clinical Pathology and Assistant Professor at Johns Hopkins.

Marie holds a Ph.D. in clinical chemistry from the University of Windsor.

Sandy Soelter is the Director of the Cell Culture and Genetic Toxicology department at MBR. Her responsibilities include acting as study director and principal investigator on research projects and programs in accordance with regulatory requirements and providing scientific and technical support for genetic toxicology testing.

Sandy has more than 20 years of GLP laboratory experience. Prior to MBR, she was at Pfizer/ Pharmacia/Searle where she gained experience in molecular biology, immunology, mammalian cell culture, and validation of cell-based assays. Sandy also has extensive experience as a Study Director and in writing regulatory reports.

Sandy received a M.S in biology with a concentration in molecular and cellular biology from Northeastern Illinois University.

Sabrina Morton serves as the Vice President of Business Operations for MBR.  Her responsibilities include overseeing day-to-day operations, managing budgets and contracts, information technology support, and ensuring quality in laboratory services.

Sabrina brings more than 20 years of experience in the pharmaceutical industry.  Prior to joining MBR, she served as the Head of Operations in Safety Sciences at Pfizer/Pharmacia and as Manager of Toxicology Operations for Searle/Monsanto.  Sabrina has extensive experience as study director/monitor for a variety of toxicology studies.

Sabrina holds an M.S. in physiology and toxicology from the Illinois Institute of Technology.  She was certified as a Diplomat of the American Board of Toxicology (DABT) in 1993.

Monique serves as the Director of Program Services for MBR. She provdes support to an area that harnesses MBR's extensive pharmaceutical industry experiences to provide technical, managerial, monitoring, and consulting services.

Monique has 15 years of experience in preclinical safety assessment of therapeutic candidates (both proteins and small molecules) at Pfizer/Pharmacia and Searle/Monsanto. She has been a toxicology leader for numerous early and late-stage drug development projects, and has experience in due diligence of drug in-license opportunities and as a Study Director/Monitor.

Monique holds a Ph.D. from the Department of Pathology at the Medical College of Virginia with postdoctoral training from that institution's Department of Pharmacology and Toxicology.

Chuck is responsible for managing assay development and validation of immunochemical techniques for both nonclinical and clinical projects involving protein drugs, biomarkers, and antibodies.

Chuck brings more than 10 years of pharmaceutical industry experience in research and development. Prior to joining MBR, he was at Pfizer/Pharmacia and Searle/Monsanto, where he developed and validated immunoassays for detecting drug candidates in support of drug discovery and development projects, using automated instrumentation to maintain high throughput for rapid sample turnaround.

Chuck received a B.S. degree in biology from the University of Illinois, Chicago. Chuck also earned a medical technology degree from Holy Cross Hospital, Chicago.

Lucy's responsibilities include overseeing day-to-day operations, ensuring quality in laboratory services, and managing all sample/data handling functions for a variety of client projects.

Lucy has seven years of experience supporting and managing regulated studies. Prior to joining MBR, she was a scientist at Pfizer/Pharmacia and Searle/Monsanto. Before Pfizer, she was a forensic scientist at the Illinois Racing Board Laboratory.

Lucy holds a B.S. in biology from Loyola University, Chicago.

Jeff is also a managing director of The Chempetitive Group, an integrated marketing company that is focused on early- to mid-stage life sciences companies. He was formerly vice president and partner for Slack Barshinger and managed the agency¹s life sciences practice and was vice president of communications for the Illinois Biotechnology Industry Organization. Jeff has also held corporate marketing and communications positions with Monsanto Company, Dade Behring, and Calgene, Inc.

Jeff received his B.A. from Columbia College, and his M.A. from Syracuse University.

Jerry Hribar serves as Scientific Director of MBR’s Structure Analysis group.  His responsibilities include overseeing a team that specializes in structure identification of small molecule metabolites and impurities using mass spectrometry and other sophisticated instruments.

Jerry has more than 32 years of experience in the pharmaceutical industry interpreting mass spectral data based on reaction pathways.  His experience spans drug discovery, development, metabolism, manufacturing and marketing products.  Prior to MBR, Jerry managed the Structure Identification Laboratory at Pfizer/Pharmacia (formerly Searle/Monsanto).  He also was director of the NIH High Resolution Mass Spectrometry Facility at Cornell University.

Jerry received his Ph.D. in organic chemistry and mass spectrometry from Wayne State University.

Jenifer Vija serves as Director of MBR’s Bioanalytical Services Department, which encompasses the Chromatography and Immunoassay groups. She works closely with Managers, Directors, and Quality Assurance to propose, schedule, and track projects and resources to achieve scientific goals and meet client timelines while maintaining high documentation standards and adhering to the appropriate regulatory guidelines.

Jennifer has more than nine years of experience in bioanalytical and analytical chemistry, including six years in the pharmaceutical industry. At NeoPharm Inc, she worked as the a Senior Scientist of in the pharmacokinetics, safety and efficacy department developing, validating, and automating bioanalytical methods for the quantification of small molecule drugs in biological matrices, including lipid encapsulated drugs and oligonucleotides.

Jennifer received a Ph.D. in analytical chemistry from the University of Washington.

Paul Donovan serves as MBR’s Controller.  His responsibilities include providing financial leadership and business guidance. 

Paul brings more than 25 years of experience in the pharmaceutical industry, including financial and business positions within Pfizer, Pharmacia, Monsanto and G.D. Searle.  While with these companies, Mr. Donovan managed multi-million dollar R&D budgets and evaluated internal and external development opportunities. He was a member of numerous development teams including third party collaborations.

Michelle Stuart provides guidance to scientists in the Immunoassay group. Her responsibilities include acting as Study Director/Principal Investigator for client-sponsored studies and research projects, assisting in the generation of Immunoassay group documentation, acting as liaison between client and external institutions, and managing staffing resources.

Michelle has six years of Immunochemistry and bioanalysis experience. Prior to joining MBR, she served as the Scientific Team Leader for HFL, Ltd., where she managed project work and results; ensured necessary customer service; provided technical expertise in Biomarker analysis; and conducted laboratory work with her team members.

Michelle received a BSc in Biochemistry from Coventry University, UK.

Peggy Tsatsos manages the Chromatography group.

Dr. Tsatsos brings more than seven years of bioanalytical experience to MBR. Prior to joining MBR, Dr. Tsatsos worked as a senior scientist for Abbott Laboratories where she led research programs in analyzing and characterizing immunosuppressive drugs, microparticles and prostate and breast cancer product lines. Prior to Abbott, she worked for Argonne National Laboratory standardizing analytical detection techniques for use with microarrays.

Dr. Tsatsos received her Ph.D. in Biochemistry from the University of Illinois Urbana-Champaign.

Don serves as the director of the Quality Assurance Department and brings more than twenty-nine years of pharmaceutical experience to MBR. Prior to joining MBR, Don worked as QA director for Pfizer. Don also has had QA management roles for Pharmacia and Monsanto in the GLP, Clinical, computer validation and GMP areas. Prior to Pfizer, he worked as a bioanalytical laboratory manager for Searle in their R&D clinical program.

Don received his Ph.D. in Analytical Chemistry from the University of Toronto, Canada.